Clinical Trial News and Research

RSS

LSDF announces new Matching grants to promote treatments for devastating medical conditions

The Life Sciences Discovery Fund today announced nearly $1 million in Matching grants to two Washington-based companies to promote translation of promising treatments for devastating medical conditions from the laboratory to the commercial marketplace.

11 Mar 2015

New method could lead to improved treatment for NPC patients

Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.

11 Mar 2015

Brain tumor experts launch revolutionary fast-track approach to cancer research

Brain tumor experts at Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center have launched a revolutionary fast-track approach to cancer research, giving new hope to brain cancer patients.

10 Mar 2015

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada.

10 Mar 2015

InMed, University of Debrecen partner to develop novel therapies to treat ocular allergies

InMed Pharmaceuticals Inc. announces it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms.

10 Mar 2015

VENITI closes $17 million in equity and debt financing

VENITI, Inc., a St. Louis, MO-based medical device company is pleased to announce that it has closed on an equity and debt financing totaling over $17 million. The equity portion, its Series C, was led by previous investors, Baird Capital and Tekla Healthcare and Tekla Life Science Investors, with strong internal participation.

10 Mar 2015

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.

From Advanced Cell Diagnostics 9 Mar 2015

G-treeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201

RegeneRx Biopharmaceuticals, Inc. has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand international development of its product candidate, RGN-259 (designated GBT-201).

9 Mar 2015

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

From Baxter International Inc. 9 Mar 2015

BMC researchers to play key role in examining best treatment for acute low back pain

Boston Medical Center researchers are part of a national clinical trial that will examine how best to treat acute low back pain and potentially prevent it from being chronic. BMC will receive $2.3 million for its role in the five-year study that was recently approved for a $14 million award by the Patient-Centered Outcomes Research Institute.

9 Mar 2015

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection.

9 Mar 2015

CPRIT awards research and recruitment grants to improve cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center researchers more than $7.5 million in research grants to improve diagnostic and therapeutic services and research relating to cancers of the brain, breast, throat, and bone, as well as to improve scientific understanding of cancer biology.

9 Mar 2015

New blood thinner reduces stroke risk in patients with atrial fibrillation

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke.

9 Mar 2015

Phase 3 trial results show that new testosterone nasal gel is effective and practical

A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

$Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures$

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. Results of the ACTIVE fracture prevention trial will be described in a late-breaking oral presentation Thursday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Researchers study safety, effectiveness of experimental Ebola vaccine following high-risk exposure

A physician who received an experimental Ebola vaccine after experiencing a needle stick while working in an Ebola treatment unit in Sierra Leone did not develop Ebola virus infection, and there was strong Ebola-specific immune responses after the vaccination, although because of its limited use to date, the effectiveness and safety of the vaccine is not certain, according to a study appearing in JAMA.

6 Mar 2015

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

6 Mar 2015

Gut bacteria may help predict risk for diabetes

The composition of intestinal bacteria and other micro-organisms--called the gut microbiota--changes over time in unhealthy ways in black men who are prediabetic, a new study finds. The results will be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.

5 Mar 2015

Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt plc, a leading global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion.

5 Mar 2015

Clinical Trial News and Research

LSDF announces new Matching grants to promote treatments for devastating medical conditions

New method could lead to improved treatment for NPC patients

Brain tumor experts launch revolutionary fast-track approach to cancer research

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

InMed, University of Debrecen partner to develop novel therapies to treat ocular allergies

VENITI closes $17 million in equity and debt financing

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

G-treeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

BMC researchers to play key role in examining best treatment for acute low back pain

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

CPRIT awards research and recruitment grants to improve cancer research

New blood thinner reduces stroke risk in patients with atrial fibrillation

Phase 3 trial results show that new testosterone nasal gel is effective and practical

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Researchers study safety, effectiveness of experimental Ebola vaccine following high-risk exposure

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Gut bacteria may help predict risk for diabetes

Mallinckrodt enters into definitive agreement to acquire Ikaria

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery